This cluster groups 2 independently calculated changes: Revenue changed across a zero base; Operating income increased 17.4%.
2 evidence-backed components· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTAllogene Therapeutics, Inc.'s latest supported as-filed period reports revenue of $4.6M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Revenue changed across a zero base; Operating income increased 17.4%.
2 evidence-backed componentsCapital expenditure changed +240.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
ALLO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001491874-26-000005SEC ↗8-KSep 2, 2026Period Aug 31, 20260001193125-26-379423SEC ↗4Aug 25, 2026Period Aug 21, 20260001628280-26-058920SEC ↗10-QAug 12, 2026Period Jun 30, 20260001628280-26-056213SEC ↗8-KAug 12, 2026Period Aug 12, 20260001628280-26-056198SEC ↗4Jul 6, 2026Period Jul 1, 20260001851044-26-000005SEC ↗4Jun 23, 2026Period Jun 18, 20260001221355-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 21, 2026Filed Oct 23, 2026 | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | Open Market SaleDirect | 36,342 | $1 | $48,698 | Form 4 ↗ |
| Aug 21, 2026Filed Aug 25, 2026 | Douglas Earl MartinSVP, General Counsel | Open Market SaleDirect | 29,697 | $2 | $62,958 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Roberts ZacharyPresident and CEO | Grant Or AwardDirect | 134,530 | $0 | $0 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | Roberts ZacharyPresident and CEO | Grant Or AwardDirect | 476,190 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Shares outstanding changed +55.7% from the comparable as-filed period. The change ranks at the 86th percentile of 7 prior comparable changes.
Stock-based compensation changed +43.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Free-cash-flow proxy changed +17.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Operating income changed +17.4% from the comparable as-filed period.
Operating cash flow changed +18.0% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Cash & equivalents changed -26.2% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001737287-26-000021| Kazam Joshua ADirector |
| Option ExerciseDirect |
| 47,700 |
| $0 |
| $0 |
| Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Kazam Joshua ADirector | Option ExerciseDirect | 47,700 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Kazam Joshua ADirector | Grant Or AwardDirect | 95,400 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | MESSEMER DEBORAH M.Director | Grant Or AwardDirect | 95,400 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Mayo StephenDirector | Grant Or AwardDirect | 144,400 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | SATO VICKI LDirector | Grant Or AwardDirect | 95,400 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | WITTE OWEN N.Director | Grant Or AwardDirect | 95,400 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Humer Franz BDirector | Grant Or AwardDirect | 95,400 | $0 | $0 | Form 4 ↗ |
| Jun 18, 2026Filed Jun 23, 2026 | Barrett Elizabeth A.Director | Grant Or AwardDirect | 95,400 | $0 | $0 | Form 4 ↗ |
| Apr 21, 2026Filed Apr 23, 2026 | Yoshiyama AnnieSVP, Finance | Open Market SaleDirect | 9,586 | $2 | $22,144 | Form 4 ↗ |
| Mar 31, 2026Filed Apr 2, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Open Market SaleDirect | 2,867 | $3 | $7,168 | Form 4 ↗ |
| Mar 16, 2026Filed Mar 18, 2026 | Beneski Benjamin MachinasSVP, Chief Technical Officer | Open Market SaleDirect | 4,835 | $2 | $11,942 | Form 4 ↗ |